|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: CHST14 |
Gene summary for CHST14 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | CHST14 | Gene ID | 113189 |
| Gene name | carbohydrate sulfotransferase 14 | |
| Gene Alias | ATCS | |
| Cytomap | 15q15.1 | |
| Gene Type | protein-coding | GO ID | GO:0005975 | UniProtAcc | Q8NCH0 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 113189 | CHST14 | LZE21T | Human | Esophagus | ESCC | 8.91e-03 | 1.62e-01 | 0.0655 |
| 113189 | CHST14 | P1T-E | Human | Esophagus | ESCC | 2.16e-03 | 1.45e-01 | 0.0875 |
| 113189 | CHST14 | P2T-E | Human | Esophagus | ESCC | 2.24e-27 | 5.39e-01 | 0.1177 |
| 113189 | CHST14 | P4T-E | Human | Esophagus | ESCC | 2.25e-34 | 7.35e-01 | 0.1323 |
| 113189 | CHST14 | P5T-E | Human | Esophagus | ESCC | 1.09e-09 | 1.67e-01 | 0.1327 |
| 113189 | CHST14 | P8T-E | Human | Esophagus | ESCC | 1.39e-13 | 2.10e-01 | 0.0889 |
| 113189 | CHST14 | P9T-E | Human | Esophagus | ESCC | 1.01e-09 | 2.88e-01 | 0.1131 |
| 113189 | CHST14 | P10T-E | Human | Esophagus | ESCC | 2.18e-26 | 4.58e-01 | 0.116 |
| 113189 | CHST14 | P11T-E | Human | Esophagus | ESCC | 5.87e-03 | 2.46e-01 | 0.1426 |
| 113189 | CHST14 | P12T-E | Human | Esophagus | ESCC | 4.88e-23 | 3.76e-01 | 0.1122 |
| 113189 | CHST14 | P15T-E | Human | Esophagus | ESCC | 1.39e-15 | 2.64e-01 | 0.1149 |
| 113189 | CHST14 | P16T-E | Human | Esophagus | ESCC | 5.01e-24 | 3.77e-01 | 0.1153 |
| 113189 | CHST14 | P20T-E | Human | Esophagus | ESCC | 1.84e-06 | 1.01e-01 | 0.1124 |
| 113189 | CHST14 | P21T-E | Human | Esophagus | ESCC | 1.49e-04 | 5.99e-02 | 0.1617 |
| 113189 | CHST14 | P22T-E | Human | Esophagus | ESCC | 4.84e-13 | 2.09e-01 | 0.1236 |
| 113189 | CHST14 | P23T-E | Human | Esophagus | ESCC | 5.90e-08 | 1.28e-01 | 0.108 |
| 113189 | CHST14 | P24T-E | Human | Esophagus | ESCC | 5.28e-06 | 1.19e-01 | 0.1287 |
| 113189 | CHST14 | P26T-E | Human | Esophagus | ESCC | 2.35e-23 | 3.98e-01 | 0.1276 |
| 113189 | CHST14 | P27T-E | Human | Esophagus | ESCC | 4.54e-10 | 1.86e-01 | 0.1055 |
| 113189 | CHST14 | P28T-E | Human | Esophagus | ESCC | 1.61e-08 | 2.11e-01 | 0.1149 |
| Page: 1 2 3 4 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00091002 | Esophagus | ESCC | glycoprotein metabolic process | 226/8552 | 387/18723 | 2.64e-07 | 3.94e-06 | 226 |
| GO:00067906 | Esophagus | ESCC | sulfur compound metabolic process | 201/8552 | 339/18723 | 2.64e-07 | 3.94e-06 | 201 |
| GO:00442725 | Esophagus | ESCC | sulfur compound biosynthetic process | 96/8552 | 148/18723 | 1.86e-06 | 2.16e-05 | 96 |
| GO:00091012 | Esophagus | ESCC | glycoprotein biosynthetic process | 181/8552 | 317/18723 | 2.54e-05 | 2.15e-04 | 181 |
| GO:00160514 | Esophagus | ESCC | carbohydrate biosynthetic process | 117/8552 | 202/18723 | 2.96e-04 | 1.79e-03 | 117 |
| GO:0006029 | Esophagus | ESCC | proteoglycan metabolic process | 48/8552 | 79/18723 | 4.93e-03 | 1.89e-02 | 48 |
| GO:0030166 | Esophagus | ESCC | proteoglycan biosynthetic process | 35/8552 | 56/18723 | 8.30e-03 | 2.94e-02 | 35 |
| GO:0006024 | Esophagus | ESCC | glycosaminoglycan biosynthetic process | 45/8552 | 75/18723 | 8.75e-03 | 3.08e-02 | 45 |
| GO:0006023 | Esophagus | ESCC | aminoglycan biosynthetic process | 47/8552 | 79/18723 | 9.29e-03 | 3.23e-02 | 47 |
| GO:00442724 | Oral cavity | OSCC | sulfur compound biosynthetic process | 82/7305 | 148/18723 | 3.71e-05 | 3.31e-04 | 82 |
| GO:00067905 | Oral cavity | OSCC | sulfur compound metabolic process | 168/7305 | 339/18723 | 4.50e-05 | 3.84e-04 | 168 |
| GO:00091001 | Oral cavity | OSCC | glycoprotein metabolic process | 185/7305 | 387/18723 | 2.37e-04 | 1.54e-03 | 185 |
| GO:00091011 | Oral cavity | OSCC | glycoprotein biosynthetic process | 151/7305 | 317/18723 | 1.01e-03 | 5.26e-03 | 151 |
| GO:00160513 | Oral cavity | OSCC | carbohydrate biosynthetic process | 97/7305 | 202/18723 | 5.50e-03 | 2.13e-02 | 97 |
| GO:000679012 | Oral cavity | LP | sulfur compound metabolic process | 106/4623 | 339/18723 | 3.36e-03 | 2.25e-02 | 106 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa00532 | Oral cavity | OSCC | Glycosaminoglycan biosynthesis - chondroitin sulfate / dermatan sulfate | 16/3704 | 21/8465 | 2.61e-03 | 6.77e-03 | 3.45e-03 | 16 |
| hsa005321 | Oral cavity | OSCC | Glycosaminoglycan biosynthesis - chondroitin sulfate / dermatan sulfate | 16/3704 | 21/8465 | 2.61e-03 | 6.77e-03 | 3.45e-03 | 16 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| CHST14 | SNV | Missense_Mutation | novel | c.810N>C | p.Glu270Asp | p.E270D | Q8NCH0 | protein_coding | tolerated(0.21) | possibly_damaging(0.579) | TCGA-AN-A04A-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| CHST14 | insertion | Frame_Shift_Ins | novel | c.811_812insCTTCCTCTACTGCTACGTCCCC | p.Asp271AlafsTer10 | p.D271Afs*10 | Q8NCH0 | protein_coding | TCGA-AN-A04A-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | ||
| CHST14 | SNV | Missense_Mutation | novel | c.731N>A | p.Arg244Gln | p.R244Q | Q8NCH0 | protein_coding | deleterious(0.02) | possibly_damaging(0.69) | TCGA-JW-A5VL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| CHST14 | SNV | Missense_Mutation | novel | c.940C>T | p.Arg314Trp | p.R314W | Q8NCH0 | protein_coding | deleterious(0.01) | possibly_damaging(0.545) | TCGA-A6-2686-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| CHST14 | SNV | Missense_Mutation | c.1000N>A | p.Glu334Lys | p.E334K | Q8NCH0 | protein_coding | tolerated(0.21) | possibly_damaging(0.833) | TCGA-AA-3966-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| CHST14 | SNV | Missense_Mutation | novel | c.1026N>G | p.Ser342Arg | p.S342R | Q8NCH0 | protein_coding | tolerated(0.32) | benign(0.006) | TCGA-AG-A00Y-01 | Colorectum | rectum adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
| CHST14 | SNV | Missense_Mutation | novel | c.794N>T | p.Arg265Ile | p.R265I | Q8NCH0 | protein_coding | tolerated(0.05) | possibly_damaging(0.674) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| CHST14 | SNV | Missense_Mutation | c.787N>C | p.Phe263Leu | p.F263L | Q8NCH0 | protein_coding | deleterious(0) | probably_damaging(0.99) | TCGA-AP-A054-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | PD | |
| CHST14 | SNV | Missense_Mutation | rs766320306 | c.687N>T | p.Glu229Asp | p.E229D | Q8NCH0 | protein_coding | tolerated(0.07) | benign(0.418) | TCGA-B5-A0JY-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD |
| CHST14 | SNV | Missense_Mutation | novel | c.955N>A | p.Val319Ile | p.V319I | Q8NCH0 | protein_coding | tolerated(0.41) | benign(0.357) | TCGA-B5-A3FC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |